Cargando...
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
Chimeric antigen receptor (CAR)‐T cell therapy is now approved in the United States and Europe as a standard treatment for relapsed/refractory B‐cell malignancies. It has also been approved recently by the Therapeutic Goods Administration in Australia and may soon be publicly reimbursed. This advanc...
Guardado en:
| Publicado en: | Clin Transl Immunology |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6526894/ https://ncbi.nlm.nih.gov/pubmed/31139410 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1050 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|